Disease Resistance Phenotyping
Disease Resistance Phenotyping - Related Videos
15:09
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
0 Views •
Cited by 22 •
2012
Fibroblasts from patients carrying mutations in Parkinson's disease-causing genes represent an easily accessible ex vivo model to study disease-associated phenotypes. Live cell imaging gives the opportunity to study morphological and functional parameters in living cells. Here we describe the preparation of human fibroblasts and subsequent monitoring of mitochondrial phenotypes.
12:18
Behavioral Phenotyping of Murine Disease Models with the Integrated Behavioral Station (INBEST)
0 Views •
Cited by 4 •
2015
Prolonged and comprehensive monitoring of mice in a home-cage environment provides a deeper understanding of aberrant behavior in murine models of brain diseases. This paper describes the Integrated Behavioral Station (INBEST) as the key component of contemporary behavioral analysis.
07:35
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
0 Views •
Cited by 14 •
2015
The use of ultra-high field MRI as a non-invasive way to obtain phenotypic information of rodent models for polycystic kidney disease and to monitor interventions is described. Compared with the traditional histological approach, MRI images can be acquired in vivo, allowing for longitudinal follow-up.
06:49
A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
0 Views •
Cited by 120 •
2015
This video protocol describes a sensitive, reliable, and quick method for evaluating the neuromuscular deficits in a transgenic mouse model of amyotrophic lateral sclerosis.
09:37
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
0 Views •
Cited by 5 •
2016
A reverse-genetics approach to understanding gene families associated with human disease is presented, using mouse as a model system, and the subsequent mouse phenotyping schedule is described. Because mice defective in a gene of interest, HtrA2, manifested Parkinsonian symptoms, the phenotyping regimen is focused on identifying neurological defects.
FAQs
Standardized conditions reduce variation unrelated to biological design, allowing response measurements to be compared across samples. Researchers can keep the disease challenge and observation framework consistent while recording symptom scores, imaging results, growth, survival, or immune responses. This makes it easier to associate differences with resistance-related properties rather than inconsistent testing conditions.
The distinction comes from the pattern and severity of measured responses after a disease challenge. Limited infection progression or minor symptoms can support a resistance interpretation, whereas pronounced symptoms, impaired growth, or reduced survival indicate susceptibility. Tolerance is assessed through how well an organism or system maintains function despite disease-related effects, using the selected outcome measures.
It tests whether an engineered change produces a functional disease-related benefit rather than only a molecular or design-level alteration. Measurements from infection progression, imaging, growth, survival, or immune responses connect the engineered feature to observable performance. This evidence supports evaluation of genetically modified organisms, gene-edited traits, biomaterials, and host-pathogen models.
A typical assay begins by applying a defined disease-causing agent to the organism, tissue, or engineered system under controlled conditions. Researchers then monitor selected responses over the course of the challenge, such as symptoms, infection progression, imaging features, growth, survival, or immune activity. Results are recorded systematically so samples can be compared using consistent criteria.
No single measurement is required for every system. Symptom scoring can capture visible disease effects, while imaging can document changes in infection or tissue condition. Growth and survival provide functional outcomes, and immune-response measurements offer additional biological evidence. Combining suitable readouts can provide a more informative assessment than relying on one observation alone.
Bioengineering studies use these measurements to evaluate disease-resistant crops, therapeutic research systems, genetically modified organisms, gene-edited traits, biomaterials, and host-pathogen models. The approach is valuable whenever a designed biological feature must be tested under a disease challenge. Its main contribution is linking engineered design choices with measurable resistance, susceptibility, tolerance, or system performance.